Page last updated: 2024-08-23

bezafibrate and glucagon

bezafibrate has been researched along with glucagon in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19902 (50.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eacho, PI; Foxworthy, PS; Hoover, DM; White, SL1
Agius, L; Alberti, KG; Gerondaes, P1
Hübinger, A; Müller, HJ; Vogelberg, KH1
Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R1

Trials

1 trial(s) available for bezafibrate and glucagon

ArticleYear
[The somatostatin infusion test for the evaluation of glucose utilization in bezafibrate medication].
    Arzneimittel-Forschung, 1984, Volume: 34, Issue:9

    Topics: Adult; Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Resistance; Somatostatin; Time Factors

1984

Other Studies

3 other study(ies) available for bezafibrate and glucagon

ArticleYear
Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes.
    Toxicology and applied pharmacology, 1990, Volume: 104, Issue:3

    Topics: Acetophenones; Animals; Autacoids; Azoles; Bezafibrate; Cells, Cultured; Clofibrate; Clofibric Acid; Dexamethasone; Dogs; Dose-Response Relationship, Drug; Female; Fibric Acids; Glucagon; Hypolipidemic Agents; In Vitro Techniques; Liver; Male; Microbodies; Microscopy, Electron; NAD; Oxidation-Reduction; Rats; Tetrazoles; Tyrosine Transaminase

1990
Fatty acid metabolism in hepatocytes cultured with hypolipidaemic drugs. Role of carnitine.
    The Biochemical journal, 1988, Jul-01, Volume: 253, Issue:1

    Topics: Animals; Bezafibrate; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransferase; Cells, Cultured; Clofibrate; Clofibric Acid; Fatty Acids; Fibric Acids; Glucagon; Humans; Hypolipidemic Agents; Insulin; Liver; Male; Rats; Rats, Inbred Strains

1988
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:2

    Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides

2010